The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel StatementVasilios G. Athyros, Christos S. Mantzoros, Theodore K. Alexandrides et al.|Metabolism|2017Cited by 251
“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL SubclassesDimitri P. Mikhailidis, Evangelos Liberopoulos, Vasilios G. Athyros et al.|Current Vascular Pharmacology|2011Cited by 197
Effects of hormonal treatment on lipids in patients with cancerTheodosios D. Filippatos, D.P. Mikhailidis, Evangelos Liberopoulos et al.|Cancer Treatment Reviews|2008Cited by 62